Stents Market by Product Type (Coronary Stents, Gastrointestinal Stents, Neurovascular Stents), Material (Metallic Stents, Polymeric Stents), Mode of Delivery, Application, End User - Global Forecast 2025-2032
Description
The Stents Market was valued at USD 13.95 billion in 2024 and is projected to grow to USD 15.01 billion in 2025, with a CAGR of 7.73%, reaching USD 25.33 billion by 2032.
A comprehensive introduction to the evolving stent ecosystem shaped by clinical innovation, regulatory rigor, and shifting health system priorities
The stent landscape sits at the confluence of advancing clinical needs, material science breakthroughs, and evolving health system economics. Over the past decade, device innovation has progressed from incremental improvements in scaffold design to the integration of novel materials and delivery mechanisms that address diverse anatomical and pathological challenges. This convergence has introduced greater therapeutic choice across cardiovascular, neurovascular, peripheral, gastrointestinal, and urological indications, while simultaneously raising the bar for regulatory rigor and clinical evidence.
As care pathways shift toward minimally invasive approaches and ambulatory settings, stent developers face new expectations around ease of use, durability, and patient-centric outcomes. Concurrently, payers and providers demand clearer value demonstrations that link device performance to reductions in downstream resource utilization. Against this backdrop, industry stakeholders must reconcile rapid technological change with the realities of procurement cycles and reimbursement constraints. Consequently, strategic clarity around product positioning, clinical differentiation, and supply chain resilience is increasingly essential for organizations seeking sustained competitive advantage.
How material breakthroughs, digital integration, and shifting care delivery are collectively redefining competitive dynamics and clinical adoption of stent technologies
Multiple transformative shifts are reshaping how stents are designed, evaluated, and adopted across care settings. First, material innovation has accelerated, with next-generation metallic alloys and polymeric constructs enabling tailored radial strength, enhanced conformability, and controlled biodegradation profiles. These material advances, in turn, permit device architectures that better match vessel biomechanics and lesion complexity, thereby expanding indications and improving long-term vessel healing.
Second, digital and imaging technologies have become integral to procedural planning and device deployment. High-resolution intravascular imaging and advanced navigation tools are facilitating more precise placement, which improves clinical outcomes and reduces procedural variability. Third, care delivery is moving toward outpatient and hybrid models, prompting device makers to optimize delivery systems for faster procedures and reduced perioperative risk. Fourth, regulatory frameworks are tightening requirements for post-market surveillance and real-world evidence generation, creating both higher barriers to entry and richer datasets to demonstrate comparative effectiveness. Finally, strategic partnerships among device innovators, contract manufacturers, and specialist clinical centers are accelerating the translation of laboratory advances into scalable clinical solutions. Collectively, these forces are redefining competitive imperatives and creating pathways for differentiated value propositions.
Evaluating the cascading consequences of the 2025 United States tariff measures on supply chains, procurement practices, and commercial strategies in the stent sector
The introduction of tariffs by the United States in 2025 has exerted a multifaceted influence on the global stent ecosystem, prompting industry participants to reassess sourcing, pricing strategies, and risk exposure. Supply chain managers have responded by diversifying procurement footprints and prioritizing dual-sourcing arrangements to mitigate concentration risk for critical components such as precision alloys and polymer feedstocks. This shift toward geographic dispersion is not instantaneous; it requires establishing validated supplier relationships, transferring complex manufacturing know-how, and ensuring regulatory-compliant quality systems across multiple sites.
Clinicians and hospital procurement teams are experiencing indirect effects as sourcing disruptions lead to variability in lead times and device SKUs available for specific procedures. In response, hospital supply chains are increasing inventory buffers for high-use devices while also engaging more closely with suppliers on forecasting and consignment arrangements. From an industry perspective, device manufacturers are accelerating localization efforts where feasible, investing in regional manufacturing capabilities to reduce tariff exposure and improve responsiveness to clinical demand.
In parallel, commercial teams are revisiting contract terms and rebate structures to reflect altered landed costs and logistics complexities. Regulatory affairs groups must also manage the implications of component substitutions and manufacturing transfers on device approvals and post-market obligations. As a result, strategic decisions about where to manufacture, which suppliers to onboard, and how to document and demonstrate supply continuity have become central to maintaining market access and preserving clinical trust.
Actionable segmentation insights that align product design, material choice, delivery mechanisms, clinical applications, and end-user dynamics for strategic prioritization
Segmentation lenses reveal where clinical need, material selection, and care pathways intersect to create differentiated demand pockets within the stent market. By product type, the landscape spans coronary stents, gastrointestinal stents, neurovascular stents, peripheral stents, and urological stents; within neurovascular offerings, devices further differentiate into extracranial carotid artery stents and intracranial stents, while peripheral solutions subdivide into carotid artery stents, femoral artery stents, iliac artery stents, and renal artery stents, and urological devices include prostatic stents and ureteral stents. Each product category carries unique design imperatives tied to anatomical constraints and clinical endpoints, which drives targeted R&D pathways and distinct clinical trial requirements.
Material-based segmentation separates metallic stents from polymeric alternatives; metallic platforms commonly rely on cobalt chromium, nitinol, platinum chromium, or stainless steel alloys, whereas polymeric options include biodegradable polymers and non-biodegradable polymers, each presenting trade-offs in terms of radial strength, long-term vessel interaction, and resorption profiles. Delivery mode further stratifies solutions into balloon-expandable and self-expanding systems, with procedural context and lesion morphology guiding selection between the two. Application segments encompass cardiovascular diseases, gastrointestinal obstructions, neurovascular conditions, oncology-related applications, peripheral artery disease, and urological disorders, and these clinical use cases impose divergent safety and efficacy thresholds. Finally, end-user segmentation includes ambulatory surgical centers, cardiology centers, hospitals, and specialty clinics; each care setting demands specific device attributes around ease of deployment, inventory management, and support services, all of which influence commercial approaches and post-market engagement models.
Strategic regional perspectives across Americas, Europe, Middle East & Africa, and Asia-Pacific that shape market entry, access, and supply resilience
Regional dynamics vary meaningfully across the Americas, Europe, Middle East & Africa, and Asia-Pacific, creating distinct opportunities and constraints for stent manufacturers and suppliers. In the Americas, procedural volumes and established reimbursement pathways support a strong focus on incremental innovation and lifecycle management of existing portfolios, while provider consolidation trends place greater emphasis on contract negotiation and total cost of ownership metrics. Transitioning to outpatient procedures in select markets also drives demand for streamlined device systems and value-based service offerings.
Within Europe, Middle East & Africa, regulatory harmonization and heterogeneous procurement landscapes necessitate a tailored approach to evidence generation and market access. Diverse payer models across the region favor different value propositions, requiring flexible clinical and economic dossiers that can be adapted for national agencies and hospital networks. The Asia-Pacific region is characterized by rapid adoption of minimally invasive technology in leading centers, alongside growing clinical capacity in emerging markets. Here, manufacturers often balance high-volume, cost-sensitive procurement in some countries with premium pricing and early adoption pockets in advanced tertiary centers. Cross-region supply strategies, regional manufacturing investments, and targeted clinical partnerships are essential levers to navigate these geographic nuances and to maintain continuity under shifting trade dynamics.
Key competitive advantages and corporate strategies that drive differentiation through technology, evidence generation, manufacturing resilience, and commercialization excellence
Competitive dynamics in the stent domain are shaped by a combination of technology leadership, breadth of clinical evidence, manufacturing excellence, and commercial agility. Leading organizations invest across the product lifecycle, from materials science and delivery system engineering to post-market data collection and clinician training programs. Strategic differentiation often emerges through proprietary alloy formulations, polymer chemistries, or delivery catheter innovations that reduce procedural complexity and improve clinical outcomes.
Partnerships and alliances accelerate time-to-clinic for novel concepts by leveraging external manufacturing capacity, hospital innovation centers, and specialized contract research organizations. In addition, companies that integrate robust real-world evidence capabilities can more effectively demonstrate comparative effectiveness and cost implications, thereby strengthening payer engagement. Operationally, firms that maintain resilient, geographically diversified manufacturing networks and agile quality systems are better positioned to respond to tariff shifts and supply disruptions. Finally, commercialization excellence relies on tailored customer support models that align with the needs of hospitals, ambulatory surgical centers, and specialty clinics, including training, procedural support, and inventory solutions that minimize clinical friction and enhance adoption.
Practical, high-impact recommendations for executives to enhance innovation pipelines, supply resilience, evidence generation, and market access execution
Industry leaders should prioritize a set of pragmatic actions to navigate the complex clinical, regulatory, and trade landscape. First, accelerate material science investments to broaden the portfolio of validated alloys and polymer systems that address unmet anatomical and therapeutic needs while maintaining robust biocompatibility profiles. Second, establish diversified supplier networks and regional manufacturing footprints to reduce single-point-of-failure exposure and to shorten lead times for critical components. Third, strengthen digital and imaging partnerships that enhance procedural precision and create complementary service offerings for clinicians.
Fourth, invest in structured real-world evidence programs that proactively capture long-term clinical outcomes and health economic data, enabling more persuasive value conversations with payers and procurement organizations. Fifth, tailor commercial models to the specific requirements of hospitals, ambulatory surgical centers, cardiology centers, and specialty clinics, ensuring training and post-sale support are aligned with end-user workflows. Sixth, embed regulatory foresight into product development to anticipate post-market surveillance demands and facilitate smoother global registrations. By executing these measures, companies can increase resilience, accelerate adoption, and improve payer and provider value recognition across diverse geographies and clinical settings.
A transparent mixed-methods research approach combining expert interviews, literature review, and triangulation to produce defensible and actionable insights
The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure a robust and transparent evidence base. Primary research included structured interviews with clinicians, procurement leaders, regulatory experts, and supply chain managers to capture firsthand perspectives on clinical needs, procurement practices, and manufacturing considerations. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, device technical specifications, and publicly available company disclosures to validate and contextualize primary findings.
Data synthesis employed triangulation between these sources to reconcile divergent viewpoints and to highlight consensus areas. The methodological framework also included scenario analysis to assess potential implications of trade policy shifts and supply interruptions. Quality assurance measures involved cross-verification of technical claims with clinical experts and regulatory specialists, along with audit trails documenting source provenance. Limitations of the approach include potential selection bias in interview sampling and the inherent lag between evolving policy measures and documented clinical adoption; these were mitigated through targeted outreach to multiple stakeholder groups and iterative validation of emerging themes.
A concise conclusion synthesizing innovation, supply chain resilience, and evidence-driven commercialization as pillars for future success in the stent domain
In summary, the stent sector is navigating a period of substantive transformation driven by material innovation, procedural digitization, changing care delivery models, and shifting trade dynamics. Manufacturers that align product development with clinician needs, invest in real-world evidence, and build geographically resilient supply chains will be best positioned to capture clinical adoption and mitigate commercial risk. Policy and tariff developments underscore the need for flexible sourcing strategies and proactive regulatory planning to preserve market access and to maintain consistent device availability for providers.
Looking ahead, the most successful organizations will be those that combine technical differentiation with operational discipline and a deep understanding of end-user workflows. Strategic partnerships across the value chain, from imaging companies to contract manufacturers and clinical centers of excellence, will accelerate commercialization and create sustainable competitive advantages. By focusing on these priorities, stakeholders can navigate near-term disruptions while laying the groundwork for enduring clinical and commercial success.
Please Note: PDF & Excel + Online Access - 1 Year
A comprehensive introduction to the evolving stent ecosystem shaped by clinical innovation, regulatory rigor, and shifting health system priorities
The stent landscape sits at the confluence of advancing clinical needs, material science breakthroughs, and evolving health system economics. Over the past decade, device innovation has progressed from incremental improvements in scaffold design to the integration of novel materials and delivery mechanisms that address diverse anatomical and pathological challenges. This convergence has introduced greater therapeutic choice across cardiovascular, neurovascular, peripheral, gastrointestinal, and urological indications, while simultaneously raising the bar for regulatory rigor and clinical evidence.
As care pathways shift toward minimally invasive approaches and ambulatory settings, stent developers face new expectations around ease of use, durability, and patient-centric outcomes. Concurrently, payers and providers demand clearer value demonstrations that link device performance to reductions in downstream resource utilization. Against this backdrop, industry stakeholders must reconcile rapid technological change with the realities of procurement cycles and reimbursement constraints. Consequently, strategic clarity around product positioning, clinical differentiation, and supply chain resilience is increasingly essential for organizations seeking sustained competitive advantage.
How material breakthroughs, digital integration, and shifting care delivery are collectively redefining competitive dynamics and clinical adoption of stent technologies
Multiple transformative shifts are reshaping how stents are designed, evaluated, and adopted across care settings. First, material innovation has accelerated, with next-generation metallic alloys and polymeric constructs enabling tailored radial strength, enhanced conformability, and controlled biodegradation profiles. These material advances, in turn, permit device architectures that better match vessel biomechanics and lesion complexity, thereby expanding indications and improving long-term vessel healing.
Second, digital and imaging technologies have become integral to procedural planning and device deployment. High-resolution intravascular imaging and advanced navigation tools are facilitating more precise placement, which improves clinical outcomes and reduces procedural variability. Third, care delivery is moving toward outpatient and hybrid models, prompting device makers to optimize delivery systems for faster procedures and reduced perioperative risk. Fourth, regulatory frameworks are tightening requirements for post-market surveillance and real-world evidence generation, creating both higher barriers to entry and richer datasets to demonstrate comparative effectiveness. Finally, strategic partnerships among device innovators, contract manufacturers, and specialist clinical centers are accelerating the translation of laboratory advances into scalable clinical solutions. Collectively, these forces are redefining competitive imperatives and creating pathways for differentiated value propositions.
Evaluating the cascading consequences of the 2025 United States tariff measures on supply chains, procurement practices, and commercial strategies in the stent sector
The introduction of tariffs by the United States in 2025 has exerted a multifaceted influence on the global stent ecosystem, prompting industry participants to reassess sourcing, pricing strategies, and risk exposure. Supply chain managers have responded by diversifying procurement footprints and prioritizing dual-sourcing arrangements to mitigate concentration risk for critical components such as precision alloys and polymer feedstocks. This shift toward geographic dispersion is not instantaneous; it requires establishing validated supplier relationships, transferring complex manufacturing know-how, and ensuring regulatory-compliant quality systems across multiple sites.
Clinicians and hospital procurement teams are experiencing indirect effects as sourcing disruptions lead to variability in lead times and device SKUs available for specific procedures. In response, hospital supply chains are increasing inventory buffers for high-use devices while also engaging more closely with suppliers on forecasting and consignment arrangements. From an industry perspective, device manufacturers are accelerating localization efforts where feasible, investing in regional manufacturing capabilities to reduce tariff exposure and improve responsiveness to clinical demand.
In parallel, commercial teams are revisiting contract terms and rebate structures to reflect altered landed costs and logistics complexities. Regulatory affairs groups must also manage the implications of component substitutions and manufacturing transfers on device approvals and post-market obligations. As a result, strategic decisions about where to manufacture, which suppliers to onboard, and how to document and demonstrate supply continuity have become central to maintaining market access and preserving clinical trust.
Actionable segmentation insights that align product design, material choice, delivery mechanisms, clinical applications, and end-user dynamics for strategic prioritization
Segmentation lenses reveal where clinical need, material selection, and care pathways intersect to create differentiated demand pockets within the stent market. By product type, the landscape spans coronary stents, gastrointestinal stents, neurovascular stents, peripheral stents, and urological stents; within neurovascular offerings, devices further differentiate into extracranial carotid artery stents and intracranial stents, while peripheral solutions subdivide into carotid artery stents, femoral artery stents, iliac artery stents, and renal artery stents, and urological devices include prostatic stents and ureteral stents. Each product category carries unique design imperatives tied to anatomical constraints and clinical endpoints, which drives targeted R&D pathways and distinct clinical trial requirements.
Material-based segmentation separates metallic stents from polymeric alternatives; metallic platforms commonly rely on cobalt chromium, nitinol, platinum chromium, or stainless steel alloys, whereas polymeric options include biodegradable polymers and non-biodegradable polymers, each presenting trade-offs in terms of radial strength, long-term vessel interaction, and resorption profiles. Delivery mode further stratifies solutions into balloon-expandable and self-expanding systems, with procedural context and lesion morphology guiding selection between the two. Application segments encompass cardiovascular diseases, gastrointestinal obstructions, neurovascular conditions, oncology-related applications, peripheral artery disease, and urological disorders, and these clinical use cases impose divergent safety and efficacy thresholds. Finally, end-user segmentation includes ambulatory surgical centers, cardiology centers, hospitals, and specialty clinics; each care setting demands specific device attributes around ease of deployment, inventory management, and support services, all of which influence commercial approaches and post-market engagement models.
Strategic regional perspectives across Americas, Europe, Middle East & Africa, and Asia-Pacific that shape market entry, access, and supply resilience
Regional dynamics vary meaningfully across the Americas, Europe, Middle East & Africa, and Asia-Pacific, creating distinct opportunities and constraints for stent manufacturers and suppliers. In the Americas, procedural volumes and established reimbursement pathways support a strong focus on incremental innovation and lifecycle management of existing portfolios, while provider consolidation trends place greater emphasis on contract negotiation and total cost of ownership metrics. Transitioning to outpatient procedures in select markets also drives demand for streamlined device systems and value-based service offerings.
Within Europe, Middle East & Africa, regulatory harmonization and heterogeneous procurement landscapes necessitate a tailored approach to evidence generation and market access. Diverse payer models across the region favor different value propositions, requiring flexible clinical and economic dossiers that can be adapted for national agencies and hospital networks. The Asia-Pacific region is characterized by rapid adoption of minimally invasive technology in leading centers, alongside growing clinical capacity in emerging markets. Here, manufacturers often balance high-volume, cost-sensitive procurement in some countries with premium pricing and early adoption pockets in advanced tertiary centers. Cross-region supply strategies, regional manufacturing investments, and targeted clinical partnerships are essential levers to navigate these geographic nuances and to maintain continuity under shifting trade dynamics.
Key competitive advantages and corporate strategies that drive differentiation through technology, evidence generation, manufacturing resilience, and commercialization excellence
Competitive dynamics in the stent domain are shaped by a combination of technology leadership, breadth of clinical evidence, manufacturing excellence, and commercial agility. Leading organizations invest across the product lifecycle, from materials science and delivery system engineering to post-market data collection and clinician training programs. Strategic differentiation often emerges through proprietary alloy formulations, polymer chemistries, or delivery catheter innovations that reduce procedural complexity and improve clinical outcomes.
Partnerships and alliances accelerate time-to-clinic for novel concepts by leveraging external manufacturing capacity, hospital innovation centers, and specialized contract research organizations. In addition, companies that integrate robust real-world evidence capabilities can more effectively demonstrate comparative effectiveness and cost implications, thereby strengthening payer engagement. Operationally, firms that maintain resilient, geographically diversified manufacturing networks and agile quality systems are better positioned to respond to tariff shifts and supply disruptions. Finally, commercialization excellence relies on tailored customer support models that align with the needs of hospitals, ambulatory surgical centers, and specialty clinics, including training, procedural support, and inventory solutions that minimize clinical friction and enhance adoption.
Practical, high-impact recommendations for executives to enhance innovation pipelines, supply resilience, evidence generation, and market access execution
Industry leaders should prioritize a set of pragmatic actions to navigate the complex clinical, regulatory, and trade landscape. First, accelerate material science investments to broaden the portfolio of validated alloys and polymer systems that address unmet anatomical and therapeutic needs while maintaining robust biocompatibility profiles. Second, establish diversified supplier networks and regional manufacturing footprints to reduce single-point-of-failure exposure and to shorten lead times for critical components. Third, strengthen digital and imaging partnerships that enhance procedural precision and create complementary service offerings for clinicians.
Fourth, invest in structured real-world evidence programs that proactively capture long-term clinical outcomes and health economic data, enabling more persuasive value conversations with payers and procurement organizations. Fifth, tailor commercial models to the specific requirements of hospitals, ambulatory surgical centers, cardiology centers, and specialty clinics, ensuring training and post-sale support are aligned with end-user workflows. Sixth, embed regulatory foresight into product development to anticipate post-market surveillance demands and facilitate smoother global registrations. By executing these measures, companies can increase resilience, accelerate adoption, and improve payer and provider value recognition across diverse geographies and clinical settings.
A transparent mixed-methods research approach combining expert interviews, literature review, and triangulation to produce defensible and actionable insights
The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure a robust and transparent evidence base. Primary research included structured interviews with clinicians, procurement leaders, regulatory experts, and supply chain managers to capture firsthand perspectives on clinical needs, procurement practices, and manufacturing considerations. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, device technical specifications, and publicly available company disclosures to validate and contextualize primary findings.
Data synthesis employed triangulation between these sources to reconcile divergent viewpoints and to highlight consensus areas. The methodological framework also included scenario analysis to assess potential implications of trade policy shifts and supply interruptions. Quality assurance measures involved cross-verification of technical claims with clinical experts and regulatory specialists, along with audit trails documenting source provenance. Limitations of the approach include potential selection bias in interview sampling and the inherent lag between evolving policy measures and documented clinical adoption; these were mitigated through targeted outreach to multiple stakeholder groups and iterative validation of emerging themes.
A concise conclusion synthesizing innovation, supply chain resilience, and evidence-driven commercialization as pillars for future success in the stent domain
In summary, the stent sector is navigating a period of substantive transformation driven by material innovation, procedural digitization, changing care delivery models, and shifting trade dynamics. Manufacturers that align product development with clinician needs, invest in real-world evidence, and build geographically resilient supply chains will be best positioned to capture clinical adoption and mitigate commercial risk. Policy and tariff developments underscore the need for flexible sourcing strategies and proactive regulatory planning to preserve market access and to maintain consistent device availability for providers.
Looking ahead, the most successful organizations will be those that combine technical differentiation with operational discipline and a deep understanding of end-user workflows. Strategic partnerships across the value chain, from imaging companies to contract manufacturers and clinical centers of excellence, will accelerate commercialization and create sustainable competitive advantages. By focusing on these priorities, stakeholders can navigate near-term disruptions while laying the groundwork for enduring clinical and commercial success.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence-guided imaging for precise stent placement to reduce procedural complications
- 5.2. Development of biodegradable polymer-free drug-eluting stents to minimize long-term inflammatory response
- 5.3. Advances in magnesium alloy bioresorbable stents offering improved vessel support and gradual absorption
- 5.4. Use of 3D printing for patient-specific stent geometries to optimize arterial flow and minimize restenosis risk
- 5.5. Adoption of nanocoating technologies to deliver targeted anti-proliferative drugs and prevent neointimal hyperplasia
- 5.6. Regulatory harmonization across major markets accelerating approval and market entry of novel stent platforms
- 5.7. Emergence of remote monitoring systems integrated with smart stent sensors for real-time restenosis detection
- 5.8. Growth of stent applications in peripheral artery disease driven by minimally invasive robotic-assisted delivery systems
- 5.9. Impact of evolving reimbursement policies on adoption rates of next-generation drug-eluting and bioabsorbable stents
- 5.10. Expansion of emerging markets penetration through cost-effective stent solutions and localized manufacturing partnerships
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Stents Market, by Product Type
- 8.1. Coronary Stents
- 8.2. Gastrointestinal Stents
- 8.3. Neurovascular Stents
- 8.3.1. Extracranial Carotid Artery Stents
- 8.3.2. Intracranial Stents
- 8.4. Peripheral Stents
- 8.4.1. Carotid Artery Stents
- 8.4.2. Femoral Artery Stents
- 8.4.3. Iliac Artery Stents
- 8.4.4. Renal Artery Stents
- 8.5. Urological Stents
- 8.5.1. Prostatic Stents
- 8.5.2. Ureteral Stents
- 9. Stents Market, by Material
- 9.1. Metallic Stents
- 9.1.1. Cobalt Chromium
- 9.1.2. Nitinol
- 9.1.3. Platinum Chromium
- 9.1.4. Stainless Steel
- 9.2. Polymeric Stents
- 9.2.1. Biodegradable Polymers
- 9.2.2. Non-biodegradable Polymers
- 10. Stents Market, by Mode of Delivery
- 10.1. Balloon-Expandable Stents
- 10.2. Self-Expanding Stents
- 11. Stents Market, by Application
- 11.1. Cardiovascular Diseases
- 11.2. Gastrointestinal Obstructions
- 11.3. Neurovascular Conditions
- 11.4. Oncology-Related Applications
- 11.5. Peripheral Artery Disease (PAD)
- 11.6. Urological Disorders
- 12. Stents Market, by End User
- 12.1. Ambulatory Surgical Centers (ASCs)
- 12.2. Cardiology Centers
- 12.3. Hospitals
- 12.4. Specialty Clinics
- 13. Stents Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Stents Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Stents Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Abbott Laboratories
- 16.3.2. Boston Scientific Corporation
- 16.3.3. Medtronic plc
- 16.3.4. BIOTRONIK SE & Co. KG
- 16.3.5. Terumo Corporation
- 16.3.6. W. L. Gore & Associates, Inc.
- 16.3.7. Cook Medical LLC
- 16.3.8. Cordis Corporation
- 16.3.9. B. Braun Melsungen AG
- 16.3.10. MicroPort Scientific Corporation
- 16.3.11. Shanghai MicroPort Medical (Group) Co., Ltd
- 16.3.12. Lepu Medical Technology Co., Ltd
- 16.3.13. Meril Life Sciences Pvt. Ltd
- 16.3.14. Sahajanand Medical Technologies Pvt. Ltd
- 16.3.15. Elixir Medical Corporation
- 16.3.16. STENTYS SA
- 16.3.17. InspireMD, Inc.
- 16.3.18. Becton, Dickinson and Company
- 16.3.19. Endologix LLC
- 16.3.20. Medinol Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
